Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis

Recruiting Observational Study
Brain Metastases Radiosurgery
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
132 (estimated)
Sponsor
Asan Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients who underwent stereotactic radiosurgery (SRS, gamma-knife radiosurgery or cyberknife radiosurgery) for brain metastases 2. Patients with lesions eligible for SRS : * One to ten newly diagnosed brain metastases * Patients without acute neurological symptom 3. P…
Contacts

Ho Sung Kim, MD, PhD

+82230105682

radhskim@gmail.com

CONTACT

Ji Eun Park, MD, PhD

+82230101505

jieunp@gmail.com

CONTACT